Cure8 regulatory brief
Researchers are studying how gut bacteria evade therapeutic phages, which could affect development of phage-based treatments for drug-resistant infections and potentially influence understanding of bacteria linked to IBD and colorectal cancer.
Insights may eventually inform new therapies against multidrug-resistant pathogens.
Researchers studying phage therapy, microbiome scientists, clinicians interested in antimicrobial resistance and translational therapeutics, and IBD researchers tracking microbiome-related disease links.
This is a funded NIH project record describing research to study how phenotypic variation in Bacteroides fragilis (and Acinetobacter baumannii) affects susceptibility to bacteriophages.
The team will use a bacterial single-cell RNA-seq method (microSPLiT), CRISPRi, phage infection assays, and mouse and metabolite exposure experiments to map how heterogeneous expression of surface components and antiphage defenses alters infection dynamics.
They also plan to isolate gut phages targeting different host phenotypic subpopulations to inform design of therapeutic phage cocktails. The project is framed as basic and translational research aimed at understanding mechanisms of phage resistance and guiding phage therapy development.
The record outlines three aims: (1) identify heterogeneous phenotypic states in B. fragilis and quantify effects on phage resistance; (2) test how gut metabolites and the mouse gut environment change subpopulation sensitivity to phage; (3) isolate gut phages and study variability-driven infection dynamics in clinical A. baumannii strains.
This summary is grounded in the NIH Reporter project abstract and is not a clinical recommendation. It describes planned and ongoing funded research rather than completed clinical results.
This entry is a project record (funded research) describing planned experiments; it does not report clinical trial results or finished findings. microSPLiT is a bacterial single-cell RNA-seq technology the team will use. Any therapeutic implications are prospective and dependent on future results.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institute of Allergy and Infectious Diseases - R01AI192998 - $874,085
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This model could improve how researchers study IBD inflammation and early colorectal cancer in a human-derived, multicellular system that reproduces neuromuscular function and immune responses. That may speed preclinical...
Researchers identified COPZ1 as a shared ferroptosis-related hub gene in Crohn’s disease, ulcerative colitis, and periodontitis, which could point to a new molecular pathway linking gut and oral inflammation and a...
The study points to CD226 (DNAM-1) being linked to inflammatory and interferon-driven programs in specific intestinal immune cells in Crohn's disease, which may be relevant to understanding disease mechanisms or...
